Fed­er­al judge scut­tles Trump's rule man­dat­ing drug prices in TV ads

6 years ago
Pharma
FDA+

ADC Ther­a­peu­tics has raised $550M-plus in its quest for their first BLA — and here’s why that’s im­por­tant

6 years ago
Financing

Ger­man can­cer biotech BioN­Tech rais­es a mam­moth $325M in lat­est round, bring­ing to­tal haul to $1.4B+

6 years ago
Financing

IGM Bio­sciences banks a $103M megaround on its quest to pi­o­neer a new kind of can­cer-fight­ing an­ti­body

6 years ago
Financing

Swiss court keeps ex-GSK sci­en­tist's broth­er be­hind bars as US push­es to ex­tra­dite him on R&D theft charges

6 years ago
China

Bil­lions on the line: Bio­Marin bus­tles past en­thused ri­val, plan­ning to launch world’s first he­mo­phil­ia A gene ...

6 years ago
Cell/Gene Tx

Medicxi, Tai­ho in­fuse €30M in­to Evotec spin­out — eye­ing can­cer meds tar­get­ing DNA dam­age re­sponse path­ways

6 years ago
Financing
Startups

Sol-Gel's rosacea drug clears late-stage hur­dle; uniQure's he­mo­phil­ia gene ther­a­py im­press­es with PhII da­ta

6 years ago
News Briefing

More de­lays? Now Roche’s CEO says he’s will­ing to wait well in­to next year to com­plete their $4.3B Spark buy­out

6 years ago
Deals

In­tra-Cel­lu­lar fin­gers a high place­bo re­sponse ex­plain­ing a PhI­II fail­ure as lead drug goes 1-and-1 in de­pres­sion

6 years ago
R&D

Ex­ec­u­tive or­der un­der con­struc­tion to peg US drug prices to low­est prices abroad, Trump says

6 years ago
Pharma

Fat­ten­ing the bankroll, Bill Haney adds can­cer R&D pow­er­house Mer­ck to Sky­hawk's ros­ter of part­ners out to drug RNA

6 years ago
Deals
R&D

Pledg­ing a come­back, Ac­er ax­es pre-com­mer­cial ops, chops staffers in wake of CRL

6 years ago
People

The chief sci­en­tist at Ger­man/US biotech hy­brid Im­mat­ics is mov­ing to the helm. Here's his to-do list

6 years ago
People
R&D

Ar­ray shows off the pos­i­tive BEA­CON CRC da­ta that helped spur Pfiz­er's $11.4B buy­out of­fer

6 years ago
R&D

Sang­amo/Pfiz­er are catch­ing up to Bio­Marin and Spark with a gene ther­a­py for he­mo­phil­ia A — can they leapfrog ...

6 years ago
R&D
Cell/Gene Tx

J&J dumps $915M de­vel­op­ment deal with Han­mi as an­oth­er Big Phar­ma aban­dons dis­as­ter-prone Ko­re­an drug­mak­er

6 years ago
Deals

Top Alzheimer’s re­searcher Paul Aisen apol­o­gizes for ethics, in­tegri­ty breach as USC pays $50M to set­tle poach­ing ...

6 years ago
R&D

Karyopharm bags an up­set win at the FDA as reg­u­la­tors OK myelo­ma drug de­spite a host of ob­jec­tions

6 years ago
R&D

Do ex­ec de­par­tures por­tend clin­i­cal dis­as­ters? An­a­lyst counts the ex­am­ples

6 years ago
R&D

Gold­man Sach­s' Ankang Li heads to biotech Terns as new CFO; SV re­cruits new part­ner for De­men­tia Dis­cov­ery Fund

6 years ago
Peer Review

GSK's Dova­to wins EU ap­proval; Red­Hill se­cures speedy re­view for H. py­lori drug

6 years ago
News Briefing

Epi­der­mol­y­sis bul­losa: FDA seeks to help de­vel­op­ment of new treat­ments

6 years ago
FDA+

Go­ing for it: GSK’s Hal Bar­ron out­lines a big PhI­II pro­gram for rheuma­toid arthri­tis — go­ing head-to-head with ...

6 years ago
People
R&D
First page Previous page 934935936937938939940 Next page Last page
A service from the Financial Times